These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 30737183)
1. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial. Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183 [TBL] [Abstract][Full Text] [Related]
2. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914 [TBL] [Abstract][Full Text] [Related]
3. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282 [TBL] [Abstract][Full Text] [Related]
4. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664 [TBL] [Abstract][Full Text] [Related]
5. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715 [TBL] [Abstract][Full Text] [Related]
6. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763 [TBL] [Abstract][Full Text] [Related]
7. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728 [TBL] [Abstract][Full Text] [Related]
8. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826 [TBL] [Abstract][Full Text] [Related]
9. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752 [TBL] [Abstract][Full Text] [Related]
10. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia. Owen RT Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493 [TBL] [Abstract][Full Text] [Related]
11. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Kuriyama A; Tabata H Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447 [TBL] [Abstract][Full Text] [Related]
12. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807 [TBL] [Abstract][Full Text] [Related]
13. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study. Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862 [TBL] [Abstract][Full Text] [Related]